---
figid: PMC9390702__i2590-017X-5-3-68-f01
figtitle: 'Targeting KRAS: Crossroads of Signaling and Immune Inhibition'
organisms:
- Homo sapiens
- Mus musculus
- gut metagenome
- Rat sarcoma virus
- NA
pmcid: PMC9390702
filename: i2590-017X-5-3-68-f01.jpg
figlink: /pmc/articles/PMC9390702/figure/i2590-017X-5-3-68-f01/
number: F1
caption: 'A schema of the RAS-RAF-MEK-ERK pathway, the immune microenvironment in
  RAS-mutant cancer, and potential therapeutic strategies targeting RAS-mutant cancer.
  Oncogenic RAS signaling promotes PD-L1 expression through stabilization of PD-L1
  mRNA, leading to immune escape in the tumor microenvironment. The inhibitors of
  the RAS-RAF-MEK-ERK pathway and the RAS-PI3K-AKT-mTOR pathway are potential agents
  to improve survival outcomes in patients with RAS mutations. *Tipifarnib is a farnesyltransferase
  inhibitor and demonstrated encouraging efficacy (objective response rate: 55%) in
  patients with head and neck squamous cell carcinoma harboring HRAS mutations.AKT:
  protein kinase B; CDK: cyclin-dependent kinase; CTLA-4: cytotoxic T-lymphocyte–associated
  antigen 4; EGFR: epithelial growth factor receptor; ERK: extracellular signal regulated
  kinase; GDP: guanosine diphosphate; GTP: guanosine triphosphate; HRAS: Harvey rat
  sarcoma virus oncogene; KRAS: Kirsten rat sarcoma viral oncogene homologue; MEK:
  mitogen-activated protein kinase; MHC-1: major histocompatibility class I; mRNA:
  messenger RNA; mTOR: mammalian target of rapamycin; NRAS: neuroblastoma rat sarcoma
  virus oncogene; PD-1: programmed cell death 1; PD-L1: programmed death-ligand 1;
  PI3K: phosphatidylinositol 3-kinase; RAF: rapidly accelerated fibrosarcoma; RAS:
  rat sarcoma virus oncogene; RNA: ribonucleic acid; RTK: receptor tyrosine kinase;
  SHP2: Src homology 2 domain-containing protein tyrosine phosphatase-2; SOS1: Son
  of sevenless 1; TCR: T-cell receptor; TKI: tyrosine kinase inhibitor.'
papertitle: 'Targeting KRAS: Crossroads of Signaling and Immune Inhibition.'
reftext: Shumei Kato, et al. J Immunother Precis Oncol. 2022 Aug;5(3):68-78.
year: '2022'
doi: 10.36401/JIPO-22-5
journal_title: Journal of Immunotherapy and Precision Oncology
journal_nlm_ta: J Immunother Precis Oncol
publisher_name: Innovative Healthcare Institute
keywords: KRAS mutation | KRAS G12C inhibitor | immune checkpoint inhibitor | tumor
  immune microenvironment
automl_pathway: 0.9632047
figid_alias: PMC9390702__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC9390702__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9390702__i2590-017X-5-3-68-f01.html
  '@type': Dataset
  description: 'A schema of the RAS-RAF-MEK-ERK pathway, the immune microenvironment
    in RAS-mutant cancer, and potential therapeutic strategies targeting RAS-mutant
    cancer. Oncogenic RAS signaling promotes PD-L1 expression through stabilization
    of PD-L1 mRNA, leading to immune escape in the tumor microenvironment. The inhibitors
    of the RAS-RAF-MEK-ERK pathway and the RAS-PI3K-AKT-mTOR pathway are potential
    agents to improve survival outcomes in patients with RAS mutations. *Tipifarnib
    is a farnesyltransferase inhibitor and demonstrated encouraging efficacy (objective
    response rate: 55%) in patients with head and neck squamous cell carcinoma harboring
    HRAS mutations.AKT: protein kinase B; CDK: cyclin-dependent kinase; CTLA-4: cytotoxic
    T-lymphocyte–associated antigen 4; EGFR: epithelial growth factor receptor; ERK:
    extracellular signal regulated kinase; GDP: guanosine diphosphate; GTP: guanosine
    triphosphate; HRAS: Harvey rat sarcoma virus oncogene; KRAS: Kirsten rat sarcoma
    viral oncogene homologue; MEK: mitogen-activated protein kinase; MHC-1: major
    histocompatibility class I; mRNA: messenger RNA; mTOR: mammalian target of rapamycin;
    NRAS: neuroblastoma rat sarcoma virus oncogene; PD-1: programmed cell death 1;
    PD-L1: programmed death-ligand 1; PI3K: phosphatidylinositol 3-kinase; RAF: rapidly
    accelerated fibrosarcoma; RAS: rat sarcoma virus oncogene; RNA: ribonucleic acid;
    RTK: receptor tyrosine kinase; SHP2: Src homology 2 domain-containing protein
    tyrosine phosphatase-2; SOS1: Son of sevenless 1; TCR: T-cell receptor; TKI: tyrosine
    kinase inhibitor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Akt1
  - Mtor
  - Cdk4
  - Ptpn11
  - Sos1
  - Nras
  - Ephb2
  - Mapk1
  - Cdk6
  - Zhx2
  - Mdk
  - Cd274
  - Pdcd1
  - Ctla4
  - Trav6-3
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - CDK4
  - PTPN11
  - SOS1
  - EPHB2
  - MAPK1
  - MAPK3
  - CDK6
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CCND1
  - CCND2
  - CCND3
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CTLA4
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
---
